Table 6.

Test performance of FIT to detect subjects with advanced adenomas (i.e. villous component, high-grade dysplasia, and/or size ≥10 mm), subdivided for location, gender, and age groups

 Detection of subjects with advanced adenomas
LocationGenderAge group
Proximal onlya≥1 DistalaWomenMen<55 y≥55 y
% (95% CI)% (95% CI)% (95% CI)% (95% CI)% (95% CI)% (95% CI)
FIT (50.0 ng/mL)
 Sensitivity0.0 (0.0–30.9)21.4 (8.3–41.0)5.3 (0.0–26.0)26.3 (9.2–51.2)9.5 (1.2–30.4)23.5 (6.8–49.9)
 Specificity96.9 (94.0–98.7)96.7 (93.9–98.5)97.7 (94.2–99.4)95.8 (90.2–98.6)96.7 (92.5–98.9)97.1 (92.8–99.2)
 PPV0.0 (0.0–36.9)40.0 (16.3–67.7)20.0 (0.5–71.6)50.0 (18.7–81.3)28.6 (3.7–71.0)50.0 (15.7–84.3)
 NPV96.2 (93.1–98.2)92.4 (88.8–95.2)90.4 (85.2–94.2)89.0 (82.2–93.8)88.6 (82.7–93.0)91.2 (85.5–95.2)
FIT (27.5 ng/mL)
 Sensitivity20.0 (2.5–55.6)32.1 (15.9–52.4)26.3 (9.2–51.2)31.6 (12.6–56.6)23.8 (8.2–47.2)35.3 (14.2–61.7)
 Specificity95.0 (91.6–97.3)94.6 (91.2–96.9)96.5 (92.6–98.7)92.4 (86.0–96.5)94.7 (89.9–97.9)95.0 (89.9–98.0)
 PPV13.3 (1.7–40.5)37.5 (18.8–59.4)45.5 (16.8–76.6)40.0 (16.3–67.7)38.5 (13.9–68.4)46.2 (19.2–74.9)
 NPV96.9 (93.9–98.6)93.2 (89.6–95.9)92.3 (87.4–95.7)89.3 (82.5–94.2)90.0 (84.3–94.2)92.3 (86.7–96.1)
  • aLocation groups defined as subjects with proximal adenomas only, and those with at least 1 distal adenoma (irrespective of proximal lesions), for the calculation of specificity, PPV, NPV, and subjects without adenomas were added to both groups, resulting in a total number of subjects of 269 and 303, respectively.